Weill Cornell Genitourinary Cancer Program

06/03/2026

“This really shows that this approach to dieting is the correct approach,” Dr. David Nanus on Weill Cornell Medicine supporting a whole-food plant-based diet for overweight/obese men treated w/ androgen deprivation therapy https://bit.ly/4viYo6t (cc: Healio)

CHICAGO — A whole-food plant-based diet can significantly increase weight loss for men with prostate cancer and overweight or obesity who are receiving androgen deprivation therapy.Data from a randomized trial, presented at ASCO Annual Meeting, showed men who received the dietary intervention....

06/02/2026

Update: A phase 2 multi-center trial evaluated the efficacy of a new therapy option for patients with metastatic castration-resistant . Dr. Cora Sternberg shares more about this : https://bit.ly/4uB33Rv

06/02/2026

Dr. Cora Sternberg was part of a presented at evaluating a combination treatment for neuroendocrine small cell or aggressive-variant . Learn more: https://bit.ly/4fLK1TH

06/01/2026

A multi-institutional study led by Weill Cornell Medicine looked at the impact of a whole-food plant-based diet for patients with androgen deprivation therapy (ADT). Dr. David Nanus shares details: https://bit.ly/4u4LLLx

06/01/2026

featuring Dr. Cora Sternberg looked at trastuzumab deruxtecan as a potential treatment for several advanced solid tumors, including : https://bit.ly/3PPFzst

05/08/2026

Dr. Daniel Margolis chimed in on new using an MRI fingerprinting technique to assess lesions:

The technique can differentiate suspicious prostate lesions from clinically insignificant lesions.

05/06/2026

A $1M dollar grant from the American Cancer Society will allow a multi-institutional team led by Dr. Bishoy Faltas to develop new therapy combinations for difficult to treat urinary tract , addressing the treatment gap for these patients:

A $1 million Research Scholar Grant from the American Cancer Society will help a multi-institution team led by Dr. Bishoy Faltas, associate professor of medicine at Weill Cornell Medicine, to develop new therapy combinations for hard-to-treat urinary tract cancers.

05/04/2026

Congratulations to the six researchers from Weill Cornell Medicine who received Young Investigator Awards from the Prostate Cancer Foundation! These three-year grants award $225,000 to postdoctoral fellows and early-career faculty conducting

Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation.

04/09/2026

Dr. Scott Tagawa joined the CancerCast podcast to talk about how prostate-specific membrane antigen (PSMA) therapy is transforming prostate cancer detection and treatment, particularly for advanced disease, and how ongoing research is expanding these treatment options for patients. Listen to learn more about why this targeted approach is so powerful: https://bit.ly/4rISr0S

04/06/2026

At , Dr. Scott Tagawa talked with Oncology Learning Network about advances in theranostics / targeted radionuclide therapy in solid tumors, including :

Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.